Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2023-12-04 00:00:00 ET · period of report 2023-12-01 · accession 0001628280-23-040625 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-04 | 2023-12-01 | NAGE | Gerber Brianna | CFO | P - Purchase | $1.41 | +5,000 | 27.4K | +22% | +$7,050 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-01 | P | A | 5,000 | $1.41 | 27,436 | D | — | — |